CpdA selectively induced GR TR and exhibited the anti-cancer effects in models of blood and solid cancers, both in vitro and in vivo, either individually or in tandem with other anti-cancer drugs (Bortezomib, MLN4924 and some others) [4,9,13,14]. The gene discussed is NR3C1; the disease is cancer.